Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fiamma Buttitta

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Cancer Research|November 4, 2005
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilizationSimona Giglio, Francesca Mancini, Francesca Gentiletti, et al.
Cancers|July 9, 2020
Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop RecordFabio Pagni, Umberto Malapelle, Claudio Doglioni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 19, 2017
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint InhibitorsAntonio Marchetti, Massimo Barberis, Renato Franco, et al.
Oncotargets and Therapy|April 17, 2019
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practiceAlessio Cortellini, Katia Cannita, Alessandro Parisi, et al.
Pathologica|August 31, 2021
Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS NetworkAntonio Marchetti, Mattia Barbareschi, Massimo Barberis, et al.
Human Mutation|January 2, 2009
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumorsFonnet E Bleeker, Simona Lamba, Sieger Leenstra, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapyMichele Milella, Carmen Nuzzo, Emilio Bria, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2015
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC PatientsAntonio Marchetti, John F Palma, Lara Felicioni, et al.
Neoplasia (New York, N.Y.)|October 2, 2009
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesAntonio Marchetti, Michele Milella, Lara Felicioni, et al.
Oncotarget|March 28, 2020
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of <i>EGFR</i> mutations in NSCLC: a new algorithm for patient selection and personalized treatmentFiamma Buttitta, Lara Felicioni, Alessia Di Lorito, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Cancer Research|November 4, 2005
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilizationSimona Giglio, Francesca Mancini, Francesca Gentiletti, et al.
Cancers|July 9, 2020
Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop RecordFabio Pagni, Umberto Malapelle, Claudio Doglioni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 19, 2017
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint InhibitorsAntonio Marchetti, Massimo Barberis, Renato Franco, et al.
Oncotargets and Therapy|April 17, 2019
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practiceAlessio Cortellini, Katia Cannita, Alessandro Parisi, et al.
Pathologica|August 31, 2021
Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS NetworkAntonio Marchetti, Mattia Barbareschi, Massimo Barberis, et al.
Human Mutation|January 2, 2009
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumorsFonnet E Bleeker, Simona Lamba, Sieger Leenstra, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapyMichele Milella, Carmen Nuzzo, Emilio Bria, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2015
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC PatientsAntonio Marchetti, John F Palma, Lara Felicioni, et al.
Neoplasia (New York, N.Y.)|October 2, 2009
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesAntonio Marchetti, Michele Milella, Lara Felicioni, et al.
Oncotarget|March 28, 2020
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of <i>EGFR</i> mutations in NSCLC: a new algorithm for patient selection and personalized treatmentFiamma Buttitta, Lara Felicioni, Alessia Di Lorito, et al.
Pageof 6